Followers | 130 |
Posts | 14996 |
Boards Moderated | 1 |
Alias Born | 06/04/2018 |
Tuesday, September 03, 2019 10:20:34 AM
NovaBay ® Pharmaceuticals, Inc . (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing Avenova ® for the domestic eye care market, announces that management will present at two upcoming investment conferences: RHK Capital 4 th Annual Disruptive Growth C...
Got this from NBY - NovaBay Pharmaceuticals to Present at Two Investment Conferences in September
Recent NBY News
- NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023 • Business Wire • 03/14/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:52:33 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 04:52:28 PM
- NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales • Business Wire • 01/30/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 01:00:12 PM
- NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network • Business Wire • 01/09/2024 02:15:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 01/04/2024 04:50:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 12:58:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:32:03 PM
- NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes • Business Wire • 12/06/2023 11:50:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:10:51 PM
- NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial Results • Business Wire • 11/09/2023 09:05:00 PM
- NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023 • Business Wire • 11/02/2023 10:50:00 AM
- NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova Programs • Business Wire • 10/11/2023 12:00:00 PM
- NovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth Conference • Business Wire • 10/02/2023 10:50:00 AM
- Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference • GlobeNewswire Inc. • 09/21/2023 01:35:00 PM
- NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft • Business Wire • 09/14/2023 12:00:00 PM
- NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft • Business Wire • 09/11/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:47:15 PM
- NovaBay Pharmaceuticals Reports Second Quarter 2023 Financial Results • Business Wire • 08/10/2023 08:05:00 PM
- NovaBay Pharmaceuticals to Hold Second Quarter 2023 Conference Call on August 10, 2023 • Business Wire • 08/08/2023 08:05:00 PM
- NovaBay Pharmaceuticals Reports Record Avenova Sales Day • Business Wire • 07/14/2023 12:30:00 PM
- NovaBay Pharmaceuticals Announces Exclusive Amazon Prime Day 2023 Promotions on All Avenova-Branded Products • Business Wire • 07/10/2023 10:50:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/07/2023 09:00:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/06/2023 09:00:31 PM
FEATURED Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • Mar 18, 2024 8:51 AM
FEATURED Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • Mar 18, 2024 8:09 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM
PSYC Begins Business Overhaul Process with Consolidation of 10 Previously Issued Convertible Debentures • PSYC • Mar 13, 2024 7:13 AM